RANI
NASDAQRani Therapeutics Holdings Inc.
Price$0.78-0.01 (-0.91%)
01:30 PM07:45 PM
News · 26 weeks34+225%
2025-12-212026-06-14
Mix2890d
- Insider10(36%)
- SEC Filings9(32%)
- Other4(14%)
- Leadership2(7%)
- Offering2(7%)
- Earnings1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chief Business Officer Mckinley Kate4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Technical Officer Javadi Alireza4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Imran Talat4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Bassan Abraham4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Rometty Lisa Ann4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Imran Mir A4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Butel Jean Luc4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Bailey Vasudev Jaiprakash4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- INSIDERSEC Form 4 filed by Director Ausiello Dennis A4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Rani Therapeutics Holdings Inc.SCHEDULE 13D/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
- SECSEC Form 8-K filed by Rani Therapeutics Holdings Inc.8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECSEC Form 424B5 filed by Rani Therapeutics Holdings Inc.424B5 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesSAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement led by a sovereign wealth fund, along with other new and existing healthcare-focused funds for the purchase and sale of 12,476,637 shares of Rani Therapeutics' Class A common stock at a purchase price of $1.07 per share and pre-funded warrants to purchase 6,214,953 shares of Class A common stock at a purchase price of $1.0699 per pre-funded warrant in a registered direct offering priced at-the-mar
- SECSEC Form 10-Q filed by Rani Therapeutics Holdings Inc.10-Q - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECRani Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits8-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- PRRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as a Strategic Advisor – SAN JOSE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the first quarter ended March 31, 2026, provided a corporate update, and announced a Chief Financial Officer transition. "
- PRRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceSAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Details below: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQDate: Tuesday, May 19, 2026 at 10:00 am E.T.Location: NASDAQ, 151 West 42nd Street, (4 Times Square), New York, NY 10036Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai SanfordFormat: Fireside Chat and 1
- SECSEC Form DEFA14A filed by Rani Therapeutics Holdings Inc.DEFA14A - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECSEC Form DEF 14A filed by Rani Therapeutics Holdings Inc.DEF 14A - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- ANALYSTLake Street initiated coverage on Rani Therapeutics with a new price targetLake Street initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $9.00
- PRRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategySAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we
- INSIDERSEC Form 3 filed by new insider Javadi Alireza3 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rani Therapeutics Holdings Inc.SCHEDULE 13G/A - Rani Therapeutics Holdings, Inc. (0001856725) (Subject)
- SECSEC Form S-8 filed by Rani Therapeutics Holdings Inc.S-8 - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
- SECSEC Form 10-K filed by Rani Therapeutics Holdings Inc.10-K - Rani Therapeutics Holdings, Inc. (0001856725) (Filer)
RANI FAQ
7 questionsWhat does Rani Therapeutics Holdings Inc. do?
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a...Where does RANI stock trade?
Rani Therapeutics Holdings Inc. (RANI) is listed on NASDAQ.What sector and industry is RANI in?
Rani Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rani Therapeutics Holdings Inc. go public?
Rani Therapeutics Holdings Inc. (RANI) completed its IPO in 2021.What are analysts saying about RANI?
Rani Therapeutics Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $900.00 price target on 2026-04-14. Recent price targets range from $900.00 to $2800.00.What companies are similar to RANI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RANI side-by-side with any of them on Quantisnow.How can I track RANI on Quantisnow?
Quantisnow aggregates Rani Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RANI to receive live email and push alerts on every new disclosure.